Your search
Results 15 resources
-
Despite current prophylaxis regimens, cytomegalovirus (CMV) is common in hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) and remains a significant cause of morbidity and mortality. Newer antiviral medications are reshaping the landscape for prevention and treatment of CMV DNAemia, infection, and disease. Letermovir is approved for CMV prevention in adult HCT patients and is attractive due to the absence of marrow suppression seen with...
-
These updated guidelines of the AST IDCOP review vaccination of solid organ transplant candidates and recipients. General principles of vaccination as well as the use of specific vaccines in this population are discussed. Vaccination should be reviewed in the pre-transplant setting and appropriate vaccines updated. Both inactivated and live vaccines can be given pre-transplant. The timing of vaccination post-transplant should be taken into account. In the post-transplant setting, inactivated...
-
The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions...
-
Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common complications affecting solid organ transplant recipients, conveying higher risks of complications, graft loss, morbidity, and mortality. Research in the field and development of prior consensus guidelines supported by The Transplantation Society has allowed a more standardized approach to CMV management. An international multidisciplinary panel of experts was convened to expand and revise evidence and...
-
Export
-
SARS-CoV-2 is transmissible through lung transplantation, and outcomes among SARS-CoV-2-infected solid organ transplant (SOT) recipients may be severe; however, transmission risk to extrapulmonary organ recipients and recent (within 30 days of transplantation) SARS-CoV-2-infected recipient outcomes are unclear.During March 2020-March 2021, potential SARS-CoV-2 transmissions through SOT reported to the Organ Procurement and Transplantation Network were investigated. Laboratory and...
-
Background: Norovirus (NoV) can cause chronic relapsing and remitting diarrhea in immunocompromised patients. Few multicenter studies have described the clinical course, outcomes, and complications of chronic NoV in transplant recipients.
-
Hepatitis B virus (HBV) can be transmitted from organ donor to recipient, but details of transmission events are not widely published. The Disease Transmission Advisory Committee (DTAC) evaluated 105 cases of potential donor derived transmission events of HBV between 2009-2017. Proven, probable or possible transmission of HBV occurred in 25 (23.8%) cases. Recipients of liver grafts were most commonly infected (20 of 21 exposed recipients) compared to 9 of 21 exposed non-hepatic recipients....
-
Abstract Background Valganciclovir is the only approved antiviral for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation (SOT). Additional approaches may be needed to improve outcomes. Methods A multicenter retrospective study from 2016 to 2019 was conducted of pediatric SOT recipients in whom at least 3 months of valganciclovir prophylaxis was planned. Episodes of CMV...
-
Background Decisions to transplant organs from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid test-positive (NAT+) donors must balance risk of donor-derived transmission events (DDTE) with the scarcity of available organs. Methods Organ Procurement and Transplantation Network (OPTN) data were used to compare organ utilization and recipient outcomes between SARS-CoV-2 NAT+ and NAT– donors. NAT+ was defined by either a positive upper or lower respiratory tract (LRT)...
-
This cohort study assesses the safety and immunogenicity of live viral vaccines in pediatric liver and kidney transplant recipients.
Filter by our tag
GUIDELINES
- AST Guidelines 2019 (2)
- ASTCT Guidelines (2)
- TTS Guidelines (1)
CORE CURRICULUM
-
INTRO SOLID ORGAN TRANSPLANT
(1)
- PEDIATRIC (1)
-
ORGANISMS
(2)
- Viruses (2)
ORGANISMS
-
VIRUSES
-
CMV
(7)
- Clinical (5)
- Epidemiology and Risk Factors (1)
- Letermovir (2)
- Maribavir (2)
-
COVID-19
(2)
- Positive Donors (2)
- Hepatitis B (1)
- Influenza (1)
- Measles (2)
- Norovirus (1)
- VZV (2)
-
CMV
(7)
DRUGS AND THERAPIES
- Antivirals (2)
PREVENTION
- Vaccination (4)
HEME-ONC AND CELLULAR THERAPIES
- BMT Guidelines (1)
- BMT-specific ID (1)
- PEDIATRIC (2)
ATC 2024 Top Papers in TID
- VIRUSES (1)